HLA-C
The MHC-I locus on chromosome 6 in the human genome comprises two groups, the highly polymorphic classical class I molecules (HLA-A, -B and -C)and the conserved non-classical molecules (HLA-E, -F and -G) (reviewed in ref. 4) . There is evidence that evolution of the HLA-A, -B and -C loci is driven by pathogen-mediated selection. The HLA-A and -B molecules in particular are highly polymorphic with the greatest variability found within the peptide-binding region, which supports their function in presentation of diverse antigens to cytotoxic T lymphocytes (CTLs). 5 HLA-C is the most recently evolved of the classical MHC-I alleles and is restricted to humans and great apes; 4, 6 and fewer alleles of HLA-C have been identified. There are also functional differences among these molecules that may restrict diversity; KIRs recognize all HLA-C allotypes, but only some HLA-A and -B allotypes. 7 HLA-C biology is still under active investigation to define its role in the immune response and the selective pressures that define its diversity (for recent review see ref. 8) .
The HLA-C protein is a heterodimer composed of a membrane-bound mature heavy chain and a light chain, Deanna A. Kulpa 1 and Kathleen L.
b 2 -microglobulin (b 2 M). HLA-C plays a dual role in that it can present antigens to CTLs and it can inhibit natural killer (NK) cell (and possibly also CTL) lysis via its interaction with inhibitory receptors. For reasons that are poorly understood, HLA-C is normally expressed on the cell surface at levels approximately 10-fold less than most HLA-A and HLA-B allotypes.
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Regulation of HLA-C surface expression
Maintenance of a low HLA-C surface expression phenotype is achieved at the transcriptional, translational and post-translational levels ( Fig. 1) . It has been known since 1995 that HLA-C heavy chain mRNA turns over at a rapid rate. 10 However, a new study has found an explanation for this observation. MicroRNA (miRNA) target sequences have now been identified in the 3 0 untranslated region (UTR) of the HLA-C gene. 12 One target site in particular was found to have functional significance for HLA-C surface expression; a single base pair insertion or deletion at position 263 downstream of the HLA-C stop codon affects the binding of miRNA-148a and correspondingly affects HLA-C surface expression (Fig. 1) . 12 In addition, HLA-C heavy chain proteins do not efficiently associate with b 2 M. 10, [13] [14] [15] The HLA-C molecules present a more restricted repertoire of peptides than HLA-A or -B, which leads to accumulation of HLA-C heavy chains in the endoplasmic reticulum and ultimately to degradation of the retained immature HLA-C molecules waiting for peptide loading (Fig. 1) . 11, 13, 16 Recent studies have demonstrated that a di-hydrophobic signal in the HLA-C cytoplasmic tail (Fig. 2) also limits cell surface expression by promoting internalization and degradation of HLA-C 16 ( Fig. 1) . Interestingly, Schaefer et al. 16 found that antigen-presenting cells (APCs) express higher levels of HLA-C on the cell surface than other cell types. The up-regulation of HLA-C occurs upon macrophage differentiation and is regulated by phosphorylation of a serine residue adjacent to the di-hydrophobic signal (S 335 ) 16 ( Fig. 2) . The tightly regulated cell surface expression of HLA-C is one indication that HLA-C plays an important role in an effective immune response.
High HLA-C expression on APCs suggests that HLA-C may serve a specific role in MHC-I pathways unique to these cell types. For example, APCs can cross-present exogenous antigens in association with co-stimulatory molecules, a process essential for the efficient priming of naive CD8 + T cells. However, uninfected APCs cross-presenting foreign antigens in association with MHC-I could also be a target of CTLs once they have developed effector functions. Lysis of cross-presenting APCs would limit the duration of effective naive T-cell priming. Because HLA-C binds to inhibitory KIR that are up-regulated upon acquisition of CTL effector functions, 17 it is possible that HLA-C plays a role in limiting CTL lysis of cross-presenting APCs. Prolonged survival of cross-presenting APCs could facilitate persistent priming of naive CD8 + T cells, which might be beneficial in chronic infection with evolving epitopes (Fig. 3) . 
HLA-C and NK cell recognition
As mentioned above, almost all HLA-C allotypes are recognized by KIRs on NK cells and mature effector CTLs. On NK cells, inhibitory KIRs monitor for 'missing self' resulting from MHC class I down-modulation on virally infected or malignant cells which otherwise would escape CTL recognition and lysis. 18, 19 HLA-C allotypes dominate over HLA-A and HLA-B allotypes as a source of ligands for KIRs 6 and inhibitory receptors for HLA-C ligands are dominant until activating signals overcome inhibition. 16, 20, 21 Activating KIRs are thought to have a weaker binding affinity for the same ligand and are probably involved in recognizing 'changed self', such as presentation of stress peptides associated with infection or malignancy by MHC class I molecules. 18 Inhibitory receptors are characterized by a long cytoplasmic tail with an immunoreceptor tyrosine inhibitory motif whereas activating KIR have a short tail lacking the tyrosine residue. 21 The KIR locus, which is located in the leucocyte receptor complex, is highly polymorphic and is comprised of a family of 14 genes, eight inhibitory, six activating and two pseudo genes. [22] [23] [24] Most of the ligands for KIRs are still undefined but the dominant ligands that have been identified so far are the C1 and C2 epitopes of HLA-C. [25] [26] [27] [28] C1 allotypes (HLA-Cw1, -Cw3, -Cw7, -Cw8, -Cw13 and -Cw14) are defined as having an asparagine at residue 80 and are the ligands for the inhibitory receptors KIR2DL2 and KIR2DL3. 20, 28, 29 C2 allotypes (HLA-Cw2, -Cw4, -Cw5, -Cw6, -Cw17 and -Cw18) have a lysine at this residue and can act as ligand for inhibitory receptor KIR2DL1 and for activating receptor KIR2DS1. 20 The MHC and KIR loci are physically unlinked and located on separate chromosomes in the human genome. Both loci are highly polymorphic, and for any functional KIR-HLA allelic pairing, it is possible that both, only one, or neither are present in an individual. 19, 20 The presence of only one allele of the KIR-HLA pair would be functionally null. 19 In addition, the frequency and intensity with which a particular KIR allele is expressed is determined during maturation and is subsequently fixed. 19 The interactions between the inhibitory receptors KIR2DL1, KIR2DL2/3 and KIR3DL1 and their HLA-C inhibitory ligands have an active role in NK cell education during their maturation. 6 These interactions are highly variable and result in a diverse response to infection and malignancy. This may be because HLA-C is the most recently evolved of the MHC class I genes and is subject to evolution and pathogen-mediated selection. 6, 20 The HLA-C allele and HIV disease
To help evade the anti-HIV CTL response, HIV encodes the accessory protein Nef, which disrupts antigen presentation in association with MHC-I by re-directing HLA-A and HLA-B molecules from the cell surface to lysosomal compartments for degradation. The HIV Nef protein limits CTL recognition by reducing the MHC class I molecules presenting HIV-derived peptides on the cell surface. 30 Down-modulation by Nef is efficient but not complete, as evidenced by the presence of anti-HIV CTLs and the emergence of HIV escape mutants capable of generating higher viral loads after evolving resistance to CTLs. 31 To disrupt the cell surface expression of HLA-A and HLA-B molecules, Nef binds to the cytoplasmic tail domain and promotes the association of the conserved MHC-I cytoplasmic tail tyrosine residue with the clathrin adaptor protein 1 (AP-1) 32 a tyrosine binding pocket in the mu subunit that is required for this interaction. Significantly, HLA-C cytoplasmic tails lack two amino acids necessary for this interaction (Fig. 2) . As a result, the HIV-1 Nef protein does not down-modulate HLA-C molecules from the cell surface 34 and so HLA-C may have a unique role in presenting antigens to CTLs in HIV disease (Fig. 4) .
HLA-C and host genetic factors that influence HIV disease progression
During primary HIV infection, the host immune response plays a critical role in controlling HIV replication and these responses typically result in a significant decrease in plasma viral load. 18, 35 At 18-24 months after seroconversion the amount of virus present has reached an equilibrium, termed the viral load set point. [36] [37] [38] Although there is great variability in the viral set point between infected individuals, many patients have stable levels exceeding 10 000 RNA copies/ml of blood. 1 In a typical course of infection, most individuals will progress to AIDS 7-11 years after infection without antiviral therapy; however, a subset of patients will have a more rapid (< 2 years) disease course or alternatively virtually no disease progression at all. [39] [40] [41] [42] To identify host genetic factors that influence HIV disease progression, a number of investigators have performed genome-wide studies to identify single nucleotide polymorphisms (SNPs) that correlate with disease outcome. One SNP upstream of HLA-C (-35C/T) has been shown to be a major determinant accounting for the viral load set point. [1] [2] [3] The -35C allele is protective, and correlates with lower viral load set points and higher CD4 + T-cell counts 2 years after seroconversion. 2, 3, 37 These data support a role for HLA-C in early or establishing stages of infection. 37 In their second genome-wide association study, Fellay et al. 3 reported that analysis of significant SNPs in the MHC class I locus is confounded by the pattern of long range linkage disequilibrium in the region. The two strongest SNPs, the HCP5 and HLA-C variants, were found to be in partial linkage disequilibrium. They report that in 95% of the samples with the rs2395029 minor allele, a polymorphism within the HCP5 gene, which is the proxy for the highly protective HLA-B*5701 allele, the HLA-C -35C SNP is also present.
3 Interestingly, they conclude that the effect of viral load set point and slower disease progression is a result of the presence of both alleles, and that analyses that are not adjusted for the presence of the HLA-C variant may in fact be over-estimating HLA-B*5701 as the sole predictor of a protective outcome. 3 It should be noted, however, that although the -35 polymorphism is present in African American populations, it does not significantly correlate with control of viral load. 43, 44 This suggests the possibility of another allelic combination present predominantly in the Caucasian populations used in these analyses that may be contributing to the observed elite controller phenotype.
Higher HLA-C surface expression is protective
Several studies have tried to determine the molecular basis for the protective phenotype of the -35C SNP. It was first reported that the -35C variant associates with higher HLA-C mRNA levels in Epstein-Barr virus-transformed B-cell lines. 45 Further studies have now demonstrated that high levels of HLA-C surface expression independently correlate with a significant protection phenotype. 44, 46 Analysis of multiple -35 SNP genotypes and HLA-C alleles demonstrate variability in surface expression of HLA-C, and those alleles that are in linkage disequilibrium with -35C specifically correlate to a higher overall surface expression, with one study reporting approximately 1Á7-fold higher on average for -35CC subjects compared with -35TT subjects. 44, 46 The -35T SNP does not correlate perfectly with low HLA-C expression levels, however, as there is overlap in the distribution of HLA-C surface expression between CC, CT and TT genotypes. 46, 47 There are individuals with a -35TT genotype that exhibit low viral-load set points that also express HLA-C mRNA levels as high as those with the -35CC genotype. 47 These data suggest that the HLA-C allele and its specific level of surface expression is the controlling factor in viral load.
One of the most significant alleles identified with higher viral loads and more rapid disease progression is HLA-Cw7, which is in strong linkage disequilibrium with -35T.
1 HLA-Cw7 is a common haplotype, and has been shown to have very low surface expression. 44 The HLA-C surface expression in -35TT individuals who were homozygous for HLA-Cw7 was five-fold lower than -35CC individuals who were HLA-Cw7 null. 44 In fact, results from Corrah et al. 44 suggest that the most significant contribution to the -35 SNP association with HIV disease progression comes from the HLA-Cw7 allele. HLA-Cw7 has been shown previously to associate with more rapid disease progression; 1 however, exclusion of individuals who were homozygous for HLA-Cw7 did not lose significance for the association of the -35CC genotype with control of HIV infection. 44 These data suggest that although low HLA-C surface expression from HLA-Cw7 is significant for rapid disease progression, the protective effect of the -35CC genotype deserves further characterization.
Significantly, the recent study by Kulkarni et al. 12 found the polymorphic miRNA-148a binding site in the HLA-C 3 0 UTR to be in strong linkage disequilibrium with the -35 SNP. Their analysis found an association between the elite control of HIV infection and a deletion at position 263 in the HLA-C 3 0 UTR, which disrupts the miRNA-148a binding site. Correspondingly, there was an association between poor control of HIV infection and an insertion polymorphism that created an miRNA-148a recognition sequence. 12 The linkage disequilibrium of the -35SNP with the 3 0 UTR miRNA-148a binding site polymorphisms offers a functional explanation for the observed differences in HLA-C surface expression among individuals and the associated control of HIV disease.
HLA-C and CTLs in HIV disease
One of the possible explanations for the observed protective effect of higher HLA-C surface expression is improved presentation of antigens by HLA-C to CTLs. Several lines of evidence support the significance of CTLs in the control of HIV infection. The appearance of HIV-specific CD8 + T cells following acute infection correlates with a reduction in viral replication and the establishment of a viral-load set point. 48 There is also evidence for the outgrowth of escape mutants within HIV epitopes targeted by CTLs, which demonstrates that CTLs exert pressure on the virus. [49] [50] [51] [52] [53] [54] [55] [56] Furthermore, a subset of MHC class I alleles confer protection from progression to AIDS. 50, 57, 58 Recent evidence indicates that the HLA-C mediated CTL response to HIV infection may be important. Adnan et al. 59 demonstrated inhibition of HIV replication in vitro using HLA-C*03, -07, -15 -restricted HIV-1-specific CTL clones. By examining HLA-driven virus evolution in an African cohort infected with HIV-1 clade C, Rousseau et al. 60 also showed that HLA-C*04-restricted CTLs behave in a functionally similar manner to HLA-Brestricted CTLs and contribute to the in vivo CTL response, although HLA-B-restricted CTLs were found to be stronger overall. Finally, Makadzange et al. 61 characterized HLA-C-restricted CTLs in an HIV-infected cohort and found that these CTLs contributed up to 54% of the total CTL response. In vitro analyses of these HLA-C-restricted CTLs demonstrated surface markers and activities to be phenotypically identical to HLA-A-or HLA-B-derived CTLs. 61 The HIV variants that alter CTL epitopes allow the virally infected cell to evade CTL recognition and their existence provides evidence that CTLs exert anti-viral pressure in vivo. These substitutions sometimes result in a fitness cost for the virus that leads to lower viral loads. 62, 63 Recently, two studies reported HIV escape mutants within CTL epitopes restricted to two different HLA-C alleles (HLA-Cw*-03 and HLA-Cw*1202). 64, 65 In the study by Honeyborne et al. 64 fitness constraints resulting from escape mutations were compensated for by mutations elsewhere within the Gag protein. The study by Honda et al. 65 described CTLs directed against HLACw*1202-restricted Pol epitopes that effectively suppressed HIV replication in vitro and that resulted in escape mutations in vivo. Interestingly, the HLA-Cw*1202 allele used in their analysis is in linkage disequilibrium with the -35CC allele. 46 These data suggest that HLA-Crestricted CTLs may contribute to the control of viral replication in vivo.
Evolution of HIV Nef in response to HLA-C allele variation
Although the -35C allele is significantly associated with lower HIV viral load set point and slower disease progression than the -35T allele, the distributions overlap. This would suggest that some of the alleles associated with the -35C SNP may not induce an effective CTL response. Alternatively, the virus may compensate by evolving new mechanisms to evade the immune system. To examine this, Specht et al. identified subjects with the protective -35CC genotype but that exhibited high viral loads. They isolated HIV nef alleles and asked whether Nef had acquired the ability to down-modulate HLA-C in these patients. 47 Interestingly, none of the Nef variants that they isolated affected HLA-C expression levels. These data suggest that there may be a substantial fitness cost to the virus if HLA-C levels are further reduced, which may be explained by the role of HLA-C as a ligand for inhibitory KIRs on NK cells (Fig. 4) . Surprisingly, Nef proteins isolated from patients with both the -35CC genotype and high viral loads had evolved to more effectively perform other Nef functions beneficial to the virus. For example, they were more efficient at down-modulating the HIV co-receptors CD4 and CXCR4, the T-cell co-stimulatory molecule CD28, and MHC class II invariant chain Ii than Nef proteins isolated from people with the -35TT genotype. 47 Hence, in some people, the benefit of higher HLA-C levels may be overcome by the evolution of a generally more pathogenic virus.
Conclusion
Infection with HIV has a variable disease course and the host factors that influence rapid versus slow disease progression are not well understood. Individuals with high HLA-C expression may benefit from more effective recognition and lysis of HIV-infected cells by HLA-Crestricted CTLs (Fig. 4) . Additionally, higher HLA-C expression in cross-presenting APCs may allow continued naive CD8 + T-cell priming during the chronic phase of infection, which would allow the development of new CTL responses to variant epitopes restricted to a variety of MHC-I allotypes (Fig. 3) . The benefit of high HLA-C expression may be limited by the inhibitory effect of HLA-C on the NK cell (and possibly CTL) response. Elevated HLA-C expression may increase the risk of some types of infections or malignancies that require an effective NK cell response for control. 66 The relative expression level of HLA-C, which has both costs and benefits, is an important phenotype that may evolve in response to pressure from pathogens.
